Prospective, randomized, phase II, non-inferiority study to evaluate the safety and efficacy of topical thrombin (Human) Grifols as adjunct to hemostasis during vascular, hepatic, soft tissue, and spinal open surgery. J Am Coll Surg 2019: 229: 497–507
Published: 29th April 2020
Authors: Minkowitz H, Navarro-Puerto J, Lakshman S, Singla S, Cousar C, Kim R et al.
This study compared two different types of thrombin (bovine and human). Some 205 procedures were included and the end point of the study was haemostasis within five minutes of completion. Rates of haemostasis were similar in the two groups: 78.3 per cent (human) and 80.3 per cent (bovine). Both thrombins were well tolerated.Pubmed Link
You may also be interested in
Gentamicin containing collagen implants and groin wound infections in vascular surgery: a prospective randomized controlled multicenter trial. Eur J Vasc Endovasc Surg 2020; 59: 635-641
Authors: Wubbeke LF, Telgenkamp B, van Boxtel T, Bolt LJJ, Houthoofd S, Vriens PW et al.
Inguinal vascular surgical wound protection by incisional negative pressure wound therapy. A randomized controlled trial—INVIPS Trial. Ann Surg 2020; 271: 48-53
Authors: Hasselmann J, Björk J, Svensson-Björk R, Acosta S
Meta-analysis and trial sequential analysis of prophylactic negative pressure therapy for groin wounds in vascular surgery. J Vasc Surg 2019; 70: 1700–1710
Authors: Antoniou GA, Onwuka CC, Antoniou SA, Russell D
A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of fibrin sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery. J Vasc Surg 2019; 70: 1642-1651
Authors: Nenezić D, Ayguasanosa J, Menyhei G, Tamas H, Mátyás L, Muluk S et al.
A randomized clinical trial evaluating negative pressure therapy to decrease vascular groin incision complications. J Vasc Surg 2018; 68: 1744-1752.
Authors: Kwon J, Staley C, McCullough M, Goss S, Arosemena M, Abai B et al.
Management of extremity fasciotomy sites prospective randomized evaluation of two techniques. Am J Surg 2018; 216: 736–739.
Authors: Johnson LS, Chaar M, Ball CG, Perez S, Nicholas JM, Wyrzykowski AD et al.
Closed incision negative pressure therapy reduces surgical site infections in vascular surgery: a prospective randomised trial (AIMS Trial). Eur J Vasc Endovasc Surg 2018; 56: 442-448.
Authors: Gombert A, Babilon M, Barbati ME, Keszei A, von Trotha KT, Jalaie H et al.
Randomized clinical trial of negative pressure wound therapy for high-risk groin wounds in lower extremity revascularization . J Vasc Surg 2017; 66: 1814-1819.
Authors: Lee K, Murphy PB, Ingves MV, Duncan A, DeRose G, Dubois L et al.
Randomized trial of a dry-powder, fibrin sealant in vascular procedures. J Vasc Surg 2015; 62: 1288–1295.
Authors: Gupta NY, Chetter I, Hayes P, O-Yurvati AH, Moneta G, Shenov S et al.
Prospective randomized double-blinded trial comparing 2 anti-MRSA agents with supplemental coverage of cefazolin before lower extremity revascularization. Ann Surg 2015; 262: 495–501.
Authors: Stone P, AbuRahma, AF, Campbell JR, Hass S, Mousa AY et al.
A prospective randomized study of heparin-bonded graft (Propaten) versus standard graft in prosthetic arteriovenous access. J Vasc Surg 2015; 62: 115–122.
Authors: Shemesh D, Goldin I, Hijazi J, Zaghal I, Berelowitz D, Verstandig A et al. et al.
Randomized controlled trial comparing the safety and efficacy between the FUSION BIOLINE heparin-coated vascular graft and the standard expanded polytetrafluoroethylene graft for femoropopliteal bypass. J Vasc Surg 2015; 61: 703–712.
Authors: Lumsden AB, Morrissey NJ, Staffa R, Lindner J, Janousek L, Treska V et al.on behalf of the Comparison of Safety and Primary Patency Between the FUSION BIOLINE Heparin-Coated Vascular Graft and EXXCEL Soft ePTFE (FINEST) Trial Co-investigators et al.